ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 95

Validation of Differential Methylation in Paternally Versus Maternally Transmitted Psoriatic Disease

Remy Pollock1, Darren O'Reilly2, Amanda Dohey2, Dianne Codner2, Vinod Chandran3, Dafna Gladman3 and Proton Rahman4, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Memorial University of Newfoundland, St. John's, NF, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: DNA Methylation, Epigenetics, genomics and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Genetics, Genomics and Proteomics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Several studies have demonstrated excessive paternal transmission of psoriasis and psoriatic arthritis (PsA). This phenomenon is thought to be mediated by genomic imprinting. We previously compared whole blood methylation patterns among PsA patients from Newfoundland, Canada and identified 90 significant CpG sites that differentiate patients with paternally and maternally-transmitted disease. This study aimed to validate previously-identified CpG sites in an independent sample of PsA patients with paternally and maternally-transmitted disease from Toronto, Canada.

Methods: All PsA patients included in the study satisfied the CASPAR criteria and had a parent with either psoriasis or PsA. Forty-six (46) PsA patients with paternally-transmitted disease were compared to 48 PsA patients with maternallytransmitted disease at 136 CpG sites on 10 different chromosomes. Percent methylation was measured at each CpG site by Sequenom EpiTyper technology, which involves bisulfite conversion followed by mass spectrometric analysis. Generated β values ranging from 0% (fully unmethylated) to 100% (fully methylated) were compared between groups using the nonparametric Mann-Whitney U test. Logistic regression models adjusting for age and sex were run to confirm the unadjusted results.

Results: PsA patients with paternally-transmitted disease were 52% female, and at the time of sample collection had a mean (SD) age of 47.7 (12.6) years, psoriasis duration of 23.7 (13.3) years, PsA duration of 14.1 (9.7) years, PASI score of 5.3 (7.2) and tender joint count of 4.9 (7.8). Patients with maternally-transmitted disease were 53% female, and had a mean age of 50.3 (11.1) years, psoriasis duration of 23.1 (12.2) years, PsA duration of 14.9 (12.0) years, PASI score of 4.5 (5.3) and tender joint count of 6.8 (8.5). Three CpG sites were significantly differentially methylated in the Toronto patients with paternally and maternally-transmitted disease. The most significant site was located within an intron of the CROCC (rootelin) gene on 1p36.13 and was hypomethylated in paternally-transmitted disease (p=0.014). Two sites within the 5’ UTR of the PACSIN1 gene on chromosome 6p21.3 were also significantly hypomethylated in paternallytransmitted disease (p=0.040 and p=0.047). After adjustment for age and sex, CpG methylation at CROCC remained significantly associated with paternally-transmitted disease (OR=0.77, 95% CI 0.60-0.99, p=0.04).

Conclusion: CpG methylation at the CROCC locus on chromosome 1p36.13 differentiates PsA patients with paternally and maternally-transmitted disease. Although CROCC is not known to be imprinted in humans, these data suggest it may play some role in the excessive paternal transmission of psoriatic disease. Further validation of these results in somatic and germ line cells are necessary.


Disclosure: R. Pollock, None; D. O'Reilly, None; A. Dohey, None; D. Codner, None; V. Chandran, None; D. Gladman, None; P. Rahman, None.

To cite this abstract in AMA style:

Pollock R, O'Reilly D, Dohey A, Codner D, Chandran V, Gladman D, Rahman P. Validation of Differential Methylation in Paternally Versus Maternally Transmitted Psoriatic Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/validation-of-differential-methylation-in-paternally-versus-maternally-transmitted-psoriatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-differential-methylation-in-paternally-versus-maternally-transmitted-psoriatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology